ClearTrial v3.2 provides more flexibility in planning and tracking complex global studies while continuing to deliver on our promise to make certain our software is intuitive and easy to use for the wide range of organizations that we serve.
Orlando, FL (PRWEB) April 12, 2010
ClearTrial (http://www.cleartrial.com), the leading provider of Clinical Trial Operations (CTO) software, today launched ClearTrial v3.2, a major upgrade to its award-winning ClearTrial PLAN, ClearTrial SOURCE, and ClearTrial TRACK products. ClearTrial v3.2 helps pharmaceutical, biotechnology and medical device companies meet the increasingly challenging demands of planning, sourcing, and tracking studies – challenges driven by a more complex and global clinical development environment.
"Our ongoing research indicates that clinical research protocols are being conducted in more global locations at the same time that they are increasingly more complex and demanding," said Kenneth Getz, Senior Research Fellow at the Tufts Center for the Study of Drug Development. "These factors present significant challenges to the industry as it strives to achieve higher levels of efficiency and productivity."
ClearTrial v3.2 is based on extensive industry research as well as comprehensive input from ClearTrial's global customer base, which ranges from the Top 20 sponsors to small biotech and medical device companies in the US, Europe, and Japan. The latest software release includes a number of new features and product enhancements that give trial sponsors more granular control over the clinical assumptions that drive study cost, resource demand, and timelines. These enhancements also provide for greater accuracy in forecasting – improving on the leading standard established by ClearTrial, which has been benchmarked to 1-5% accuracy when compared with actual study costs.
For global studies and for trial sponsors entering new and emerging countries to conduct trials, ClearTrial v3.2 expands on the software's already extensive, country-specific clinical intelligence. By including labor rates for each country, as well as intelligence around tasks affecting study timelines – such as site activation and regulatory delays – ClearTrial v3.2 makes it easier to model "what-if" scenarios and to generate fast and accurate forecasts of study costs, resource demand, and timelines in any region.
"As our customers’ clinical study processes become more global and more complex, the ClearTrial software continues to lead the market in support of such demands," said Mike Soenen, ClearTrial President and CEO. "ClearTrial v3.2 provides more flexibility in planning and tracking complex global studies while continuing to deliver on our promise to make certain our software is intuitive and easy to use for the wide range of organizations that we serve."
ClearTrial v3.2 New Features Summary
Flexible Enrollment Specification – ClearTrial v3.2 now provides both global and region-specific definition of study enrollment period and distribution. Enrollment distribution has been extended to allow weekly distributions. These new capabilities will enable the user to better accommodate differences in global enrollment performance.
Enhanced Site Approval Forecasting – ClearTrial v3.2 has enhanced its site approval forecasting capabilities to now allow region-specific site approval schedules and the definition of user defined site approval curves. These new features will allow the user to more accurately model site approval schedules.
Advanced Pass Through Costs Definition – ClearTrial v3.2 allows the user greater flexibility in defining pass through and miscellaneous costs. Costs can now be defined at a study or location level, be driven by specific study milestones, and be distributed based on pre-defined distribution curves. These new features will enable customers to more accurately assign and distribute pass through costs resulting in more precise forecasting and budgeting.
Expanded Country-specific Industry Intelligence – ClearTrial v3.2 expands the embedded clinical intelligence of the software to more than 80 countries worldwide. Featuring country-specific awareness for labor rates as well as for tasks affecting study timelines – such as site activation and regulatory delays – ClearTrial v3.2 supports the increasingly global nature of studies. This expanded capability makes it easier to model "what-if" scenarios that include the emerging countries and regions experiencing rapid growth in clinical trials.
Extended Global Currency Support – ClearTrial v3.2 has extended its global currency support to allow entry of alternate currencies for any study assumption that requires a monetary value. Alternate currencies are automatically converted based on predefined exchange rate conversion rules and on-demand reports can be printed in any currency of choice. These new capabilities will improve study planning in multiple geographies and eliminate manual and error prone currency conversions.
Reporting and Visualization – ClearTrial v3.2 delivers a host of additional tabular and graphical reports to its already extensive library of planning, forecasting and budgeting reports and graphs. These new reports will dramatically improve visibility across the lifecycle of a study.
ClearTrial is the leading provider of Clinical Trial Operations (CTO) software, linking clinical planning, forecasting, and tracking of operational and financial performance in a single, integrated system. ClearTrial’s award-winning software helps life sciences companies streamline their clinical operations from Plan to Payment™ without sacrificing quality of results, providing executives and functional leaders in clinical operations, resource planning, finance, outsourcing, and project management with a common platform that promotes speed, accuracy, and consistency throughout the organization. For more information please visit http://www.cleartrial.com.
ClearTrial® and the ClearTrial logo are registered trademarks owned by ClearTrial, LLC, which may be registered in certain jurisdictions. Any other company or product names mentioned in this release are hereby acknowledged as registered trademarks or trademarks of their respective owners.
For more information contact:
+1 630.986.9800 x112